Patients with biochemical recurrence after radical prostatectomy and radiotherapy with a PSA doubling-time (DT) of ≤ 12 months.
No hormonal therapy within the last 12 months or recovered testosterone levels.
PSMA PET negative result for local recurrence; presence of distant metastases is allowed: (cN0, cM0/cM1).
Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1
Patients must have adequate bone marrow reserve: WBC ≥1.5 x 109 /L, Platelets ≥100 x 109 /L and Haemoglobin ≥9 g/dL.
Patients must have adequate renal function with eGFR ≥ 50mL/min/1.73m2 using the Modification of Diet Renal Disease (MDRD) equation and an Albumin level of ≥2.5 g/dL.
Patients must be able to sign Informed Consent Form.
You may not be if
Concomitant participation in any other interventional trial.
Concurrent severe oncological and medical conditions that result in patients not having a life expectancy of longer than one year.
Presence of clinically relevant somatic or psychiatric diseases that might interfere with the objectives and assessments of the study.
Complete urinary out-flow obstruction or severe unmanageable urinary incontinence.
Clareo Health | PSMA-RLT in Biochemically Recurrent PCa
